Cladribine tablets as therapy for advanced relapsing-remitting multiple sclerosis: a 4-year follow-up real-world, multi-center, retrospective, cohort study

Cladribine tablets as therapy for advanced relapsing-remitting multiple sclerosis: a 4-year follow-up real-world, multi-center, retrospective, cohort study

IntroductionCladribine tablets (CladT) are a high-efficacy disease-modifying therapy recommended for the treatment of relapsing–remitting multiple sclerosis (RRMS) particularly in early disease. This study is aimed to evaluate the long-term efficacy of CladT in population of Polish RRMS patients, wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Aleksandra Pogoda-Wesołowska, Adam Stępień, Marcin Wnuk, Monika Marona, Elżbieta Tokarz-Kupczyk, Karolina Piasecka-Stryczyńska, Konrad Rejdak, Anna Jamroz-Wiśniewska, Monika Adamczyk-Sowa, Katarzyna Kubicka-Bączyk, Iwona Kurkowska-Jastrzębska, Katarzyna Kurowska, Przemysław Puz, Alina Kułakowska, Monika Chorąży, Waldemar Brola, Halina Bartosik-Psujek
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Neurology
Subjects:
cladribine
relapsing-remitting multiple sclerosis
safety
efficacy
real world evidence
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2025.1626317/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2025.1626317/full

Similar Items